Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer

Rona Yaeger; Riccardo Mezzadra; Jenna Sinopoli; Yu Bian; Michelangelo Marasco; Esther Kaplun; Yijun Gao; HuiYong Zhao; Arnaud Da Cruz Paula; Yingjie Zhu; Almudena Chaves Perez; Kalyani Chadalavada; Edison Tse; Sudhir Chowdhry; Sydney Bowker; Qing Chang; Besnik Qeriqi; Britta Weigelt; Gouri J. Nanjangud; Michael F. Berger; Hirak Der‐Torossian; Kenna Anderes; Nicholas D. Socci; Jinru Shia; Gregory J. Riely; Yonina R. Murciano‐Goroff; Bob T. Li; James G. Christensen; Jorge S. Reis‐Filho; David B. Solit; Elisa de Stanchina; Scott W. Lowe; Neal Rosen; Sandra Misale

doi:10.1158/2159-8290.30849256

Abstract

C106 cell lines single cell sequencing analysis

Related Publications

Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel

Takashi Fujishita , Massimo Loda , Ross E. Turner +4 more

Objective: Regimens with prolonged infusions of taxanes have been developed for patients with cancer to overcome drug resistance. Our objective of the present...

2003 Oncology 18 citations

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

Lili Liu , Sanford D. Markowitz , Stanton L. Gerson

Cells with the mutator phenotype are tolerant to methylating damage from N-methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanine, exhibit replication repair errors, and have ...

1996 PubMed 237 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian , Hubing Shi , Qi Wang +13 more

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel clas...

2010 Nature 2132 citations

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

James Bean , Gregory J. Riely , Marissa N. Balak +4 more

Abstract Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to ...

2008 Clinical Cancer Research 276 citations

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Saskia M. Brachmann , Irmgard Hofmann , Christian Schnell +6 more

NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical trials. We profiled this compound against a panel of breast tumor cell lines to identify the patient popul...

2009 Proceedings of the National Academy o... 316 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

Download PDF (Free) View on DOI.org

Social Impact

Altmetric

Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

CrossRef

Cite This

APA Style

                            
                                    Rona Yaeger, 
                                
                                    Riccardo Mezzadra, 
                                
                                    Jenna Sinopoli
                                
                                et al.
                            
                            (2025). 
                            Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30849256

Identifiers

DOI: 10.1158/2159-8290.30849256

Data Quality

Data completeness: 70%

Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer